Potential role of 68Ga- and 177Lu-cyclic pentapeptides for in-vivo targeting CXCR4 receptor expression in chemotherapy relapse MCL patient

Document Type : Case report

Authors

Department of Nuclear Medicine & PET Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Abstract

Objective(s): High levels of CXCR4 expression in patients with mantle cell lymphoma is associated with poor prognosis. Various molecular techniques used are unable to specify the metastatic disease burden. Cyclic pentapeptides act as CXCR4 antagonists hence are functional markers of in-vivo CXCR4 receptor expression. In this view, the theragnostic complex of radiolabeled 68Ga- and 177Lu-cyclic pentapeptides was developed to in-vivo target the CXCR4 receptor expression.
Methods: Bone marrow aspiration and flow cytometry were performed to examine the fraction of lymphoid cells and immunophenotyping respectively. In-vitro CXCR4 receptor expression in the biopsied sample was determined using immunohistochemistry and flow cytometry molecular techniques. Diagnostic imaging using 68Ga-cyclic pentapeptide was performed to check the in-vivo CXCR4 expression in chemotherapy relapse MCL patient. Dosimetry studies in the same patient was performed with different time-point imaging to calculate the residence time and predict the critical organ.
Results: Bone marrow aspiration indicated ~75% atypical lymphoid cells. Flow cytometric immunophenotyping revealed positivity for CD19, CD20, CD79b, Anti-kappa markers. IHC results showed high nuclear positivity. Approximately 86.11% of the cell population showed CXCR4 positive expression. Diagnostic imaging using 68Ga-cyclic pentapeptide showed high tracer avidity in the mesenteric mass at L4 level. The avidity of both 68Ga- and 177Lu- cyclic pentapeptide radiotracers was noted in the mesenteric mass at the L4 level. Dosimetry study using 177Lu-cyclic pentapeptide indicated kidneys as the critical organ with max residence time of 5.39 h.
Conclusion: Theragnostic complex of radiolabelled 68Ga/177Lu- cyclic pentapeptides have the potential to in-vivo target the CXCR4 receptor expression.

Keywords

Main Subjects

References

  1. Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Tomita S, et al. Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. British Journal of Cancer. 2008; 98(10):1682-9.
  2. Nikkhoo B, Jalili A, Fakhari S, Sheikhesmaili F, Fathi F, Rooshani D, et al. Nuclear pattern of CXCR4 expression is associated with a better overall survival in patients with gastric cancer. Journal of oncology. 2014; 2014(1): 808012.
  3. Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. The Korean journal of internal medicine. 2014; 29(6):785.
  4. Bao Y, Wang Z, Liu B, Lu X, Xiong Y, Shi J, et A feed- forward loop between nucleartranslocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis. Oncogene. 2019; 38(6): 881-95.
  5. Schottelius M, Herrmann K, Lapa C. In vivo targeting of CXCR4-new horizons. Cancers. 2021; 13(23):5920.
  6. Weiss ID, Jacobson O. Molecular imaging of chemokine receptor CXCR4. Theranostics. 2013; 3(1):76.
  7. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nuclear medicine and biology. 2006; 33(4): 489-94.
  8. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. Journal of Nuclear Medicine. 2009; 50(7): 1124-30.
  9. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4. Bioorganic & medicinal chemistry. 2009; 17(4): 1486-93.
  10. Lakhanpal T, Shukla J, Kumar R, Singh H, Malhotra P, Khadwal A, et al. Abstract A10: Radiolabelled AMD3100 for the management of malignant lymphoma: Translational study. Blood Cancer Discovery. 2022; 3(5-Suppl): A10.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 14, Issue 1
January 2026
Pages 117-121

Files

Share

How to cite

Statistics